HUP9901051A2 - 5-(2-Etil-2H-tetrazol-5-il)-1,2,3,6-tetrahidro-1-metil-piridin alkalmazása traumás agykárosodások kezelésére alkalmas gyógyászati készítmények előállítására - Google Patents

5-(2-Etil-2H-tetrazol-5-il)-1,2,3,6-tetrahidro-1-metil-piridin alkalmazása traumás agykárosodások kezelésére alkalmas gyógyászati készítmények előállítására

Info

Publication number
HUP9901051A2
HUP9901051A2 HU9901051A HUP9901051A HUP9901051A2 HU P9901051 A2 HUP9901051 A2 HU P9901051A2 HU 9901051 A HU9901051 A HU 9901051A HU P9901051 A HUP9901051 A HU P9901051A HU P9901051 A2 HUP9901051 A2 HU P9901051A2
Authority
HU
Hungary
Prior art keywords
treatment
traumatic brain
tetrazol
tetrahydro
ethyl
Prior art date
Application number
HU9901051A
Other languages
English (en)
Hungarian (hu)
Inventor
Brian R. Pike
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of HUP9901051A2 publication Critical patent/HUP9901051A2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HU9901051A 1995-11-06 1996-11-05 5-(2-Etil-2H-tetrazol-5-il)-1,2,3,6-tetrahidro-1-metil-piridin alkalmazása traumás agykárosodások kezelésére alkalmas gyógyászati készítmények előállítására HUP9901051A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK123295 1995-11-06
PCT/DK1996/000458 WO1997017074A1 (en) 1995-11-06 1996-11-05 Treatment of traumatic brain injury

Publications (1)

Publication Number Publication Date
HUP9901051A2 true HUP9901051A2 (hu) 2000-03-28

Family

ID=8102484

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901051A HUP9901051A2 (hu) 1995-11-06 1996-11-05 5-(2-Etil-2H-tetrazol-5-il)-1,2,3,6-tetrahidro-1-metil-piridin alkalmazása traumás agykárosodások kezelésére alkalmas gyógyászati készítmények előállítására

Country Status (18)

Country Link
EP (1) EP0866706A1 (cs)
JP (1) JPH11514654A (cs)
KR (1) KR19990067353A (cs)
AU (1) AU706594B2 (cs)
BG (1) BG63150B1 (cs)
BR (1) BR9611396A (cs)
CA (1) CA2234824A1 (cs)
CZ (1) CZ287441B6 (cs)
EA (1) EA000531B1 (cs)
HU (1) HUP9901051A2 (cs)
IS (1) IS4726A (cs)
NO (1) NO982036L (cs)
NZ (1) NZ321546A (cs)
PL (1) PL326490A1 (cs)
SK (1) SK58198A3 (cs)
TR (1) TR199800801T2 (cs)
WO (1) WO1997017074A1 (cs)
ZA (1) ZA969320B (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013096A1 (es) * 1997-07-01 2000-12-13 Lundbeck & Co As H Sal de adicion de acido maleico de 5-(2-etil-2-h-tetrazol-5-il)-1-metil- 1,2,3,6-tetrahidropiridina, composicion farmaceutica que la contiene, su usoen terapia y metodo de preparacion de la misma.
RU2266737C1 (ru) * 2004-04-12 2005-12-27 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Россиской Академии Наук Препарат для лечения геморрагического инсульта и способ лечения геморрагического инсульта
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
US5328925A (en) * 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5330994A (en) * 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives

Also Published As

Publication number Publication date
EP0866706A1 (en) 1998-09-30
NZ321546A (en) 2000-12-22
SK58198A3 (en) 1998-10-07
TR199800801T2 (xx) 1998-08-21
AU706594B2 (en) 1999-06-17
ZA969320B (en) 1997-05-30
CZ287441B6 (en) 2000-11-15
AU7490096A (en) 1997-05-29
NO982036L (no) 1998-06-25
EA000531B1 (ru) 1999-10-28
BR9611396A (pt) 1999-07-13
MX9803432A (es) 1998-09-30
KR19990067353A (ko) 1999-08-16
WO1997017074A1 (en) 1997-05-15
CA2234824A1 (en) 1997-05-15
BG102480A (en) 1999-01-29
IS4726A (is) 1998-04-27
JPH11514654A (ja) 1999-12-14
EA199800434A1 (ru) 1998-10-29
NO982036D0 (no) 1998-05-05
CZ138998A3 (cs) 1998-10-14
BG63150B1 (bg) 2001-05-31
PL326490A1 (en) 1998-09-28

Similar Documents

Publication Publication Date Title
HUP9901051A2 (hu) 5-(2-Etil-2H-tetrazol-5-il)-1,2,3,6-tetrahidro-1-metil-piridin alkalmazása traumás agykárosodások kezelésére alkalmas gyógyászati készítmények előállítására
HUP9904525A2 (hu) S-(-)-N-Propargil-1-amino-indán tartalmú neurológiai rendellenességek kezelésére alkalmas gyógyszerkészítmények
DE3876877D1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
EP0784429A4 (en) Method and formulation of stimulating nitric oxide synthesis
RU95114405A (ru) Применение рилузола в качестве лекарственного средства для лечения неврологических нарушений, вызванных травмами и способ получения лекарственного средства
AU9189301A (en) Use of substituted imidazo(1,2-A)pyridine-, imidazo(1,2-A)pyrimidine and imidazo(1,2-A)pyrazine-3-YL-amine derivatives for producing NOS-inhibiting medicaments
HUT59313A (en) Process for producing pharmaceutical composition comprising flupirtin as active ingredient and suitable for combatting muscular tensions
CY1105507T1 (el) Υποκατεστημενες πυραζολο- και θειαζολοπυριμιδινες
NZ234672A (en) N-(1,2,3,4-tetrahydro-9-acridinyl)amide and carbamate derivatives and pharmaceutical compositions
DE3875769D1 (de) Therapeutische nukleoside.
Lienemann et al. Naltrexone for treatment of self-injury.
WO2001089537A3 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
NO903384D0 (no) Fremgangsmaate for fremstilling av 4-(n-substituert amino)-2-butynyl-1-urinstoffer og -tiourinstoffer og derivater derav.
ATE169500T1 (de) Verwendung von guanosin zur herstellung von arzneimitteln zur behandlung von zerebralen funktionsstörungen
EP0294914A3 (en) Nedocromil for the treatment of dermatological disorders
TR199901304A2 (xx) Spiro $Piperidin-4,1'-Pirrolo $3,4-c]Pirrol ]
DE69306990D1 (de) Physostigmin-Derivate, ihre Verwendung und sie enthaltende pharmazeutische Formulierungen
GR3006606T3 (cs)
NO169539C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive kondenserte diazepinoner
Gould et al. Electrocardiographic normalization after cerebral vascular accident
DE345883T1 (de) Verwendung von dapiprazol zur herstellung eines arzneimittels zur verhinderung des toleranzentwicklung bei der analgetischen behandlung mit morphin.
ATE268599T1 (de) Verwendung von beta-naphtaquinon derivaten zur herstellung eines arzneimittels mit einem hemmenden effekt auf die glutamatfreisetzung durch das gehirn
SU1291153A1 (ru) Способ лечени неврологических расстройств,обусловленных т желой черепно-мозговой травмой
NO20013480L (no) Legemiddel for torr hud
WO2025043213A3 (en) Therapeutic compounds and methods